Indication Selection for a Platform Company: The Faustian Dilemma

At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients.  Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.  Specifically, many...

Key trends impacting Japan partnering

Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies. Doing deals is never easy, no matter the geography. However, it does seem that negotiating with Japanese companies...

The Best Buyers Are The Best Sellers

As it is often necessary to structure creative deals with deferred and/or ongoing value delivered to the seller, an important but frequently overlooked component of the deal process is to position your company as the ideal partner for the acquired asset. Recently, the...

Maintaining Deal Momentum in the Summertime

Fresh off Memorial Day Weekend, I had to face the reality that summer is here! When the kids are out of school, the regular schedules that we have enjoyed throughout the year become replaced by a multitude of summer camps, travels, and family fun. But as we know,...